THE ROLE OF CA 19.9 IN PREDICTING THE OPERABILITY OF CARCINOMA PANCREAS
DOI:
https://doi.org/10.22159/ajpcr.2024v17i10.52152Keywords:
Carcinoma of Pancreas, Cancer antigen 19-9,, Resectability.Abstract
Objectives: Adenocarcinoma of the pancreas remains a relatively incurable disease despite advances in surgical care. Approximately 25% of patients will be found to have unresectable tumors during surgery even though computed tomography (CT) has demonstrated that they are resectable. There is a controversy regarding the use of cancer antigen 19-9 (CA 19-9) to decide the resectability of pancreatic adenocarcinoma [1]. Our aim is to study the use of CA 19-9 in determining the operability of carcinoma pancreas [2].
Methods: This was a prospective study which included 69 patients and the study period was from December 2021 to December 2022. Data were collected from all patients with carcinoma of the pancreas who underwent surgical management. CA 19-9 levels were measured and recorded [3]. During surgery, the operative findings on resectability were documented and tabulated against corresponding CA 19-9 levels and contrast-enhanced CT (CECT) findings.
Results: Of the 69 patients who were operated on, 38 patients had resectable tumors and underwent the Whipples procedure and 31 of them had non-resectable tumors and had to undergo palliative bypass procedures. Among the 31 patients whose tumors were non-resectable, only four were diagnosed non-resectable preoperatively with CECT, and the other 27 were found to be non-resectable only during surgery. That shows the relevance of this study. Of the 31 non-resectable cases, 14 (45.2%) patients had elevated CA 19-9 values of more than 501, and the rest 17 (54.8%) patients had low CA 19-9 values. Among the 38 resectable cases, 12 patients (31.6%) had elevated CA 19-9 more than 501, and 26 patients (68.4%) had low values. In conclusion, among non-resectable cases, 45.2% had raised CA 19-9, and among operable cases, 31.6% showed raised CA 19-9. Hence, CA 19-9 seems to be an insignificant predictor of tumor resectability [4].
Conclusion: It was found that the need for a pre-operative predictor for resectability of carcinoma pancreas is relevant while considering mortality and morbidity in operating carcinoma pancreas cases. On evaluating CA 19-9 as a pre-operative predictor, we found that CA 19-9 has no significant role as an indicator of local advancement or metastasis. Hence, we cannot consider CA 19-9 as a predictor of resectability of carcinoma pancreas preoperatively [5].
Downloads
References
Pandiaraja J, Viswanathan S, Antomy TB, Thirumuruganand S, Kumaresan DS. The role of CA19-9 in predicting tumour resectability in carcinoma head of pancreas. J Clin Diagn Res. 2016;10:PC06-9. PMCID: PMC4843310
Chung KH, Ryu JK, Lee BS, Jang DK, Lee SH, Kim YT. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer. J Gastroenterol Hepatol. 2016;31(2):506-12. doi: 10.1111/jgh.13075
Terraneo L, Avagliano L, Caretti A, Bianciardi P, Tosi D, Bulfamante GP, et al. Expression of carbohydrate-antigen sialyl-Lewis a on colon cancer cells promotes xenograft growth and angiogenesis in nude mice. Int J Biochem Cell Biol. 2013;45(12):2796-800. doi: 10.1016/j. biocel.2013.10.003
Navaneethan U, Lourdusamy V, Poptic E, Hammel JP, Sanaka MR, Parsi MA. Comparative effectiveness of pyruvate kinase M2 in bile, serum carbohydrate antigen 19-9, and biliary brushings in diagnosing malignant biliary strictures. Dig Dis Sci. 2015;60(4):903-9. doi: 10.1007/s10620-014-3397-7
Liu L, Xu H, Wang W, Wu C, Chen Y, Yang J, et al. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer. 2015;136:2216-27. PMID: 25273947
Yeo CJ, Cameron JL. Pancreatic cancer. Curr Probl Surg. 1999;36(2): 59-152.
Mittendorf EA, Shifrin AL, Inabnet WB, Libutti SK, McHenry CR, Demeure MJ. Islet cell tumors. Curr Probl Surg. 2006;43(10):685-765. doi: 10.1067/j.cpsurg.2006.07.003
Available from: https://www.med.upenn.edu
Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1997;4(7):551-6. doi: 10.1007/BF02305535
Mah’moud M, Anderson M, Schellenberg R, Beckham M. A rare cause of melena due to acute upper gastrointestinal bleeding 867. Am J Gastroenterol. 2012;107:356.
Published
How to Cite
Issue
Section
Copyright (c) 2024 DR RENJIN R P NAVANEETHAM, jijin
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
